Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: Cancer. 2023 Nov 10;130(5):702–712. doi: 10.1002/cncr.35103

Table 2:

Efficacy Outcomes

No. of patients (%)
Best Overall Response (n=14)
 Complete Response 0
 Partial Response 0
 Stable Disease 13 (92.9%)
 Progression of Disease 1 (7.1%)
Median PFS (months, 95% CI) (n=14) 9.7 (3.8–11.8)
Median OS (months, 95%CI) (n=14) 18.0 (11.8–29.9)
Reasons for Discontinuation (n=16)
 Progression of disease 10 (62.5%)
 Toxicity 2 (12.5%)
 Refusal of further treatment 4 (25%)

PFS, Progression-free survival

OS, Overall survival